|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| {{CMG}}
| | #REDIRECT [[Dalteparin#Pharmacology]] |
| | |
| '''For patient information, click [[Dalteparin (patient information)|here]]'''
| |
| | |
| '''For drug information on Dalteparin, click [[Dalteparin|here]]'''
| |
| | |
| ==Overview==
| |
| '''Dalteparin''' is a [[low molecular weight heparin]]. It is marketed as Fragmin by [http://www.eisai.com Eisai]. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of [[deep vein thrombosis]] and [[pulmonary embolism]].
| |
| | |
| The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism, dalteparin was more effective than [[coumarin]] in reducing the risk of recurrent embolic events.<ref>{{cite journal | author=Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M | title=Low-molecular-weight heparin versus a [[coumarin]] for the prevention of recurrent venous thromboembolism in patients with cancer | journal=N Engl J Med | year=2003 | pages=146-53 | volume=349 | issue=2 | id=PMID 12853587}}
| |
| </ref>
| |
| | |
| ==See also==
| |
| *[[Dalteparin Sodium]]
| |
| *[[Heparin]]
| |
| | |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{Antithrombotics}}
| |
| | |
| [[Category:Anticoagulants]]
| |
| [[Category:Drugs]]
| |
| | |
| | |
| [[nn:Dalteparin]]
| |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |